


Accepted Manuscript

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement

Marina Tuyishime, Matt Danish, Amy Princiotta, Marie K. Mankowski, Rae Lawrence, Henry-Georges Lombart, Kirill Esikov, Joel Berniac, Kuang Liang, Ji Jingjing, Roger G. Ptak, Navid Madani, Simon Cocklin

PII: S0960-894X(14)01084-1
DOI: <http://dx.doi.org/10.1016/j.bmcl.2014.10.027>
Reference: BMCL 22082



To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 25 July 2014
Revised Date: 6 October 2014
Accepted Date: 8 October 2014

Please cite this article as: Tuyishime, M., Danish, M., Princiotta, A., Mankowski, M.K., Lawrence, R., Lombart, H-G., Esikov, K., Berniac, J., Liang, K., Jingjing, J., Ptak, R.G., Madani, N., Cocklin, S., Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement, *Bioorganic & Medicinal Chemistry Letters* (2014), doi: <http://dx.doi.org/10.1016/j.bmcl.2014.10.027>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement

Marina Tuyishime^a, Matt Danish^a, Amy Princiotta^b, Marie K. Mankowski^c, Rae Lawrence^d, Henry-Georges Lombart^e, Kirill Esikov^e, Joel Berniac^e, Kuang Liang^f, Ji Jingjing^f, Roger G. Ptak^c, Navid Madani^b, and Simon Cocklin^a

^aDepartment of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USA

^bDepartment of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, Massachusetts, USA

^cDepartment of Infectious Disease Research, Southern Research Institute, 431 Aviation Way, Frederick, MD 21701, USA

^dCresset, New Cambridge House, Bassingbourn Road, Litlington, Cambridgeshire, UK

^eAsisChem, Inc., 313 Pleasant St, Watertown, MA 02472

^fHD Biosciences Co., Ltd., 590 Ruiqing Road, Zhangjiang East Campus, Pudong, Shanghai 201201, P.R. China

* Corresponding author. Simon Cocklin, Ph.D., Drexel University College of Medicine, Rooms 10302-10306, Department of Biochemistry & Molecular Biology, 245 North 15th Street, Philadelphia, PA 19102. Tel: Office – 1-215-762-7234, Lab – 1-215-762-4979. Fax: 1-215-762-4452.

E-mail address: scocklin@drexelmed.edu

Abstract

With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with *in silico* predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors.

Keywords:

Field-based virtual screening

Three-dimensional virtual screening

HIV-1 Env

Antiviral

Bioisostere

Entry inhibitor

Field-based scaffold hopping

Abbreviations

ADME, absorption, distribution, metabolism, and excretion

AMLV, amphotropic murine leukemia virus

BBB, blood–brain barrier

BIF, bioisostere factor

CNS, central nervous system

DCM, dichloromethane

DiEA, diisopropylethylamine

DIPEA, N,N-diisopropylethylamine

DMF, dimethylformamide

EtOAc, ethyl acetate

HATU, hexafluorophosphate

hERG, human ether-à-go-go-related gene

HIA, human intestinal absorption

HPLC, high-performance liquid chromatography

HR, heptad repeat

IC₅₀, half-maximal inhibitory concentration

PBMCs, peripheral blood mononuclear cells

Pd/C, palladium on carbon

TC₅₀, half-maximal toxic concentration

TFA, trifluoroacetic acid

THF, tetrahydrofuran

With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. The entry of HIV-1 into permissible cells is a complex series of events orchestrated by the viral envelope glycoprotein complex, the only exposed viral components on the virion surface. Being the only viral products accessible to the host cell immune system, the Env glycoproteins gp120 and gp41 have evolved several strategies to mask functionally important regions from the neutralizing antibody response. These strategies include the presence of surface-exposed variable loops on gp120, a high degree of glycosylation, the lability and defectiveness of many envelope glycoprotein spikes (possible immunologic decoys), and conformational flexibility.¹⁻⁴

The Env complex is organized on the virion surface as trimeric spikes composed of three gp120 molecules noncovalently linked to three gp41 molecules. The heavily glycosylated surface gp120⁵ contains a core composed of conserved regions (C1 to C5) and hypervariable regions that are mostly disulfide-constrained, surface-exposed loop structures (V1 to V5) that retain a large degree of flexibility.^{4, 6-9} The transmembrane glycoprotein gp41 contains the fusion peptide that is inserted into the membrane of the target cells,¹⁰ as well as two heptad repeat (HR) domains (aminoterminal or HR1 and carboxyterminal or HR2) that are implicated in the formation of a six-helix-bundle fusion intermediate via a conformational change following receptor interaction. HIV-1 infection usually occurs only after two sequential and specific binding steps: first, the Env gp120 protein binding to the CD4 antigen present in CD4⁺ T cells, monocyte/macrophages, and other immune and nonimmune cells; and second, gp120 binding to a member of the chemokine receptor subfamily, within the large G protein-coupled family of receptors, mainly CCR5 and/or CXCR4.

Advances in knowledge of the molecular mechanisms of HIV-1 entry have allowed the discovery and development of molecules that target discrete steps in the entry process and

have shown success in the clinic. Successful examples include maraviroc (Selzentry; Pfizer, New York, NY), which binds to CCR5 and blocks the interaction of the Env complex with the coreceptor, and enfuvirtide (Fuzeon; Hoffman-La Roche, Nutley, NJ), which binds to gp41 and stops the fusion of the viral and cell membrane. However, as of yet, no gp120-targeted therapies have been approved for use in the clinic.

In the HIV-1 entry field, two main Env-targeted inhibitor chemotypes predominate: the NBD-556 analogues¹¹ and the BMS-378806 analogues (**Figure 1**).¹² NBD-556 and its analogues bind to the conserved CD4-binding site in gp120 and block the interaction of the Env complex with cellular CD4.¹³⁻¹⁵ The binding site for BMS-378806 and its analogues is poorly understood, and based on resistance mutation data it may actually be a composite site composed of regions of gp120 and gp41.¹⁶ The mechanism of action of BMS-378806 and its derivatives is also under debate, with some studies claiming a CD4 binding inhibition mechanism and others describing an allosteric mechanism that prevents the propagation of the receptor binding signals from gp120 to gp41.^{17, 18} Given the huge therapeutic potential of inhibiting HIV-1 entry, the development of new chemotypes that target viral entry with broad activities is highly desirable. In this study we describe the use of high-content field-based pharmacophore screening as a first step in identifying new chemotypes for this inhibitor class.

To date, the piperazine-based entry inhibitors as first described by Bristol-Myers Squibb¹² are the most broadly acting and potent HIV-1 entry inhibitors. This indicates that the binding site for these compounds, although currently not well described, is well conserved and available for targeting on the virion and that compounds such as BMS-663068 may have great therapeutic value. In fact, the entry inhibitor BMS-663068 recently performed favorably in a phase IIb clinical trial (presented at the Conference on Retroviruses and Opportunistic Infections, March 3–March 6, 2014, Boston MA).

Although the agents are potent and have a broad therapeutic spectrum, the piperazine class of entry inhibitors developed by Bristol-Myers Squibb has been plagued by the problems

of low solubility and poor intrinsic dissolution properties. To circumvent these issues, a prodrug approach was adopted. BMS-663068 is a phosphonooxymethyl prodrug of BMS-626529^{14,16-18} designed to have increased solubility in the gut. The prodrug is thought to be cleaved by alkaline phosphatase, located on the luminal surface of the small intestine brush border membranes, releasing BMS-626529, which is then rapidly absorbed.¹⁹ Despite the success of this approach, an entry inhibitor candidate with more intrinsic druglike properties would be preferable.

As a first step towards discovering entry inhibitor candidates with intrinsic druglike properties, we conducted a series of field-based three-dimensional similarity virtual screening experiments using Blaze (Cresset, Litlington, UK) with a high-content field-based pharmacophore template derived from BMS-626529^{17, 19-21} (Forge/FieldTemplater, Cresset) in order to identify novel scaffolds that could function as entry inhibitors. To perform a Blaze virtual screen, an active ligand in its three-dimensional bioactive conformation should be used as a search query. In the absence of structural information, a binding mode hypothesis may be calculated.

As no structural information is currently available for BMS-626529 in its target-bound state, we used FieldTemplater (Forge) to determine a hypothesis for the three-dimensional conformation adopted in binding to the target using field and shape information to create a template using compounds BMS-626529, BMS-488043, and BMS-378806.^{16, 22} The FieldTemplater-derived hypothesis for the bioactive conformation was then annotated with its calculated field points, resulting in a three-dimensional field point pattern. The field point pattern provides a condensed representation of the compound's shape, electrostatics, and hydrophobicity. It is well established that when two diverse structures have conformations with similar field point patterns, they are experienced by the receptor in a similar fashion.²³⁻³³ The field-based alignment for the three selected templating molecules is shown in **Figure 2**.

The field point pattern for the hypothesized three-dimensional bioactive conformation of BMS-626529 was subsequently used to query a database of approximately 6 million commercially available compounds using Blaze. The steps involved in the Blaze virtual screening procedure are shown schematically in **Figure 3**. The Blaze procedure resulted in the rank ordering of the top 1000 Blaze library compounds whose three-dimensional arrangements of field points had similarities to that of the BMS-626529 template structure. Fifty compounds were chosen and purchased for biological testing using the single-round infection assay.³⁴ The structures of the selected compounds are shown as supplementary data. Those compounds found to be active and specific, as judged by their activity against HIV-1_{YU-2} Env pseudotyped and amphotropic murine leukemia virus (AMLV) Env pseudotyped HIV-1 virus, are shown in **Table 1**. Five compounds with specific anti-HIV-1 activity were discovered using this approach with half-maximal inhibitory concentrations (IC_{50}) in the range of 13 to 150 μ M. Compound **11** was found to be the most potent, inhibiting HIV-1_{YU-2} with an IC_{50} value of 13.1 ± 1.7 μ M.

The active and specific compounds identified from this study, despite showing a degree of chemical diversity, all share a piperazine core comparable to the Bristol-Myers Squibb compounds. Therefore, we investigated whether the piperazine core could be replaced with another moiety that would function in the same capacity but be chemically distinct. Pfizer reported a study in which replacement of an *N*-methylpiperazine in a lead compound, JNJ-7777120, with 2-methyloctahydropyrrolo[3,4-*c*]pyrrole led to a compound that retained binding affinity and selectivity but also had improved resistance to metabolism.³⁵ We therefore decided to determine whether this dipyrrolidine group could successfully replace the piperazine in compound **11**. *In silico* bioisostere replacement (scaffold-hopping) experiments using Spark (Cresset, UK) conducted to assess the potential for this group to substitute the piperazine in **11** indicated that it may be a viable, if not imperfect replacement. This conclusion was based upon the value of the calculated bioisostere factor (BIF%), a rescaled score, which indicates how much better or worse the replacement is compared with simply capping the attachment point(s)

with hydrogen(s). Positive BIF% values indicate good bioisosteres; negative values correspond to replacements where the geometry of the original molecule is reproduced; however, the fragment is not a good mimic of the replaced part.

A BIF% of 57 was obtained for the dipyrrolidine group, and therefore this replacement for piperazine was investigated. Substitution of the piperazine core in **11** with 2-methyloctahydropyrrolo[3,4-c]pyrrole yielded compound **SC04** ([5-(1,2-dihydro acenaphthylene-5-carbonyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-phenyl-methanone]), a novel compound that retains the properties of **11**, albeit with lower potency (IC_{50} HIV-1_{YU-2} = 70 ± 6 μ M; IC_{50} HIV-1_{JR-CSF} = 100 ± 30 μ M).

Having identified a new scaffold, we focused on redesigning compound **SC04** to improve its potency and to remove any potential toxophores. The head region of **SC04**, like compound **11**, is an acenaphthene group, which may be carcinogenic owing to its potential to intercalate into DNA sequences. Moreover, several studies by Bristol-Myers Squibb have demonstrated that this head region greatly influences the potency of compounds in the piperazine class. Subsequently, in order to improve the potency of **SC04**, we downloaded from PubChem 453 compounds that displayed similarity to BMS-488043. These compounds were exhaustively fragmented (Spark DBGen, Cresset, UK), and we used the resulting fragments in iterative Spark experiments, seeking fragments that could function as bioisosteric substitutions for the acenaphthene moiety but with greater potential for hydrogen bonding interactions. This resulted in the identification of two head groups, 7-chloro-4-methoxy-1H-pyrrolo[2,3-c]pyridine and 4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridine, with BIF% values (compared with acenaphthene) of 57 and 64, respectively. Two compounds bearing these head groups were synthesized (**SC07** and **SC08**) and assessed in the single-round infection assay. Owing to the relative decreased sensitivity of HIV-1_{JR-CSF} to **SC04**, as compared with HIV-1_{YU-2}, this isolate was selected for use in potency optimization. Both compounds were specific to HIV-1 (no inhibition of AMLV-

pseudotyped HIV-1) and inhibited HIV-1_{JR-CSF} pseudotyped HIV-1 virus with IC₅₀ values of $0.98 \pm 0.06 \mu\text{M}$ and $0.09 \pm 0.01 \mu\text{M}$, for **SC07** and **SC08**, respectively (**Table 2**).

The head group of **SC08** is the same as in BMS-488043.^{36, 37} Replacement of the methoxy in the 7 position on the azaindole ring with a methyltriazole greatly improved the potency of the compound, resulting in the creation of BMS-626529.^{38, 39} Therefore, we explored this substitution in **SC08** to determine whether it would result in a similar enhancement of potency (**SC11**). **SC11** was synthesized and tested for specificity and activity against HIV-1_{JR-CSF} using the single-round infection assay. **SC11** displayed greatly enhanced potency as compared with **SC08**, retaining HIV-1 specificity and inhibiting HIV-1_{JR-CSF} with an IC₅₀ value of $0.0008 \pm 0.0004 \mu\text{M}$ (**Table 2**).

Synthesis and assessment of **SC11** revealed that the dipyrrolidine core can support compounds of nanomolar potency that prevent HIV-1 entry. The next step was to analyze the predicted ADME properties (absorption, distribution, metabolism, and excretion) of this compound and compare them with those of the BMS piperazine-based entry inhibitors (**Figure 4**). To accomplish this comparison, we used a combination of computationally guided bioisosteric replacement using Spark (focusing on the terminal phenyl group of **SC11**) and *in silico* prediction of druglike metrics of the results as implemented in the oral non-central nervous system (CNS) drug profile in StarDrop 5.5 (Optibrium, Ltd., Cambridge, UK).⁴⁰

Optibrium's oral non-CNS drug profile is composed of the following metrics: logS (intrinsic aqueous solubility); classification for human intestinal absorption; logP (octanol/water); hERG (human ether-à-go-go-related gene) pIC₅₀ (mammalian cells); cytochrome P450 CYP2D6 classification; cytochrome P450 CYP2C9 pKi values; classification of P-glycoprotein transport; classification of blood-brain barrier (BBB) penetration; and predicted BBB penetration value. The models and their respective importance to the profile are shown in **Figure 4a**.

Details for the specific models are provided in the StarDrop Reference Guide from Optibrium and are online at the StarDrop FAQs

(<http://www.optibrium.com/community/faq/adme-qsar-models>). A probabilistic scoring algorithm⁴¹ is then used to combine the model predictions in the oral non-CNS drug profile into an overall score.

This combined Spark/StarDrop analysis suggested that a simple replacement of phenyl with cyclohexene may be a good transformation to perform in order to improve ADME properties while retaining the potency associated with the dipyrrolidine scaffold. StarDrop analysis of the cyclohexene variant of **SC11** (designated **SC26**) versus BMS-663068 using the oral non-CNS drug profile provided scores for **SC26** and BMS-663068 of 0.3815 ± 0.2323 and 0.0799 ± 0.1014 , respectively (**Figure 4b**). For reference, scores range from 0 to 1, with 0 suggesting extremely non-druglike, and 1 suggesting the perfect drug.

Given two oral non-CNS drug profile scores with errors corresponding to 1 standard deviation:

$$X_1 \pm \sigma_1$$

$$X_2 \pm \sigma_2;$$

and assuming that the error is normally distributed, the difference in the scores will take a normal distribution with mean $X_1 - X_2$ and standard deviation given by $\sqrt{\sigma_1^2 + \sigma_2^2}$. Therefore, the probability that $X_1 > X_2$ is the probability that $X_1 - X_2 > 0$ was calculated in Excel (Microsoft; Redmond, WA) using the NORMDIST function. This analysis predicted an 88% likelihood that **SC26** has better druglike properties than BMS-663068. Thus, we synthesized compound **SC26** and subjected it to specificity and potency analysis using the single-round infection assay. Gratifyingly, this compound exhibited IC_{50} values of 2.0 ± 0.1 nM and 0.6 ± 0.01 nM against HIV-1_{JR-CSF} and HIV-1_{HxBc2}, respectively (**Table 2**).

Because it demonstrated good potency against two isolates in the single-round infection assay as well as specificity to HIV-1, we next sought to quantify the potency of **SC26** against the fully infectious virus. Moreover, this assay was performed using healthy, primary cells to gain

further insight into potential toxicities of the compound towards natural target cells. Additionally, as a key issue in the development of novel HIV drugs is their ability to inhibit the replication of genetically diverse isolates (especially isolates from the most globally prevalent subtypes A, B, C, and D), we chose to assess the potency of **SC26** to inhibit the replication of isolates from subtypes A, B, C, and D in primary human peripheral blood mononuclear cells (PBMCs).⁴²⁻⁴⁴ Concomitantly, we assessed the toxicity of **SC26** to the PBMCs using an MTS assay. The results of these analyses are summarized in **Table 3**. As can be observed from the IC₅₀ values, the potency of **SC26** against different isolates ranges quite dramatically, most likely reflecting differences in the binding site between subtypes. Moreover, **SC26** had no effect on the replication of an HIV-2 isolate, mirroring the specificity analyses using the AMLV pseudotyped recombinant HIV-1 virus, and further demonstrating specificity to HIV-1.

In summary, we have identified a novel scaffold for the HIV-1 Env-directed entry inhibitors using field-based computational methods and multiparameter optimization. The most potent in the new class of dipyrrolodine-scaffolded entry inhibitors displayed potency comparable to the BMS piperazine-based entry inhibitors but was characterized by an improved predicted ADME profile. Like the BMS piperazine-based entry inhibitors, the new dipyrrolodine scaffold displayed varying degrees of potency against HIV-1 isolates from different subtypes, probably reflecting isolate-specific differences in the binding site on Env. Further investigation and determination of the exact binding site of these class of entry inhibitors will undoubtedly be invaluable in the redesign and optimization of such compounds, while illuminating a new site of vulnerability in the Env complex of HIV-1. Taken as a whole, these results extend the chemotypes for this class of HIV-1 inhibitor and validate the use of multiparameter optimization using high-content three-dimensional field-based models, bioisosteric replacement, and consideration of druglike metrics in drug design.

Acknowledgements

This work was supported in part by NIH/NIAID grant 1R21AI104354-01A1 (Cocklin, PI) and W. W. Smith Charitable Trust grant #A1301 (Cocklin, PI). We thank Diana Winters (Academic Publishing Services, Drexel University College of Medicine) for proofreading the manuscript.

References

1. Kwong, P. D.; Doyle, M. L.; Casper, D. J.; Cicala, C.; Leavitt, S. A.; Majeed, S.; Steenbeke, T. D.; Venturi, M.; Chaiken, I.; Fung, M.; Katinger, H.; Parren, P. W.; Robinson, J.; Van Ryk, D.; Wang, L.; Burton, D. R.; Freire, E.; Wyatt, R.; Sodroski, J.; Hendrickson, W. A.; Arthos, J. *Nature* **2002**, *420*, 678.
2. Modrow, S.; Hahn, B. H.; Shaw, G. M.; Gallo, R. C.; Wong-Staal, F.; Wolf, H. *Journal of virology* **1987**, *61*, 570.
3. Wei, X.; Decker, J. M.; Wang, S.; Hui, H.; Kappes, J. C.; Wu, X.; Salazar-Gonzalez, J. F.; Salazar, M. G.; Kilby, J. M.; Saag, M. S.; Komarova, N. L.; Nowak, M. A.; Hahn, B. H.; Kwong, P. D.; Shaw, G. M. *Nature* **2003**, *422*, 307.
4. Wyatt, R.; Sodroski, J. *Science* **1998**, *280*, 1884.
5. Leonard, C. K.; Spellman, M. W.; Riddle, L.; Harris, R. J.; Thomas, J. N.; Gregory, T. J. *The Journal of biological chemistry* **1990**, *265*, 10373.
6. Kwong, P. D.; Wyatt, R.; Robinson, J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. *Nature* **1998**, *393*, 648.
7. Rizzuto, C. D.; Wyatt, R.; Hernandez-Ramos, N.; Sun, Y.; Kwong, P. D.; Hendrickson, W. A.; Sodroski, J. *Science* **1998**, *280*, 1949.
8. Wyatt, R.; Kwong, P. D.; Desjardins, E.; Sweet, R. W.; Robinson, J.; Hendrickson, W. A.; Sodroski, J. G. *Nature* **1998**, *393*, 705.
9. Moore, J. P.; Sattentau, Q. J.; Wyatt, R.; Sodroski, J. *Journal of virology* **1994**, *68*, 469.
10. Bosch, M. L.; Earl, P. L.; Fargnoli, K.; Picciafuoco, S.; Giombini, F.; Wong-Staal, F.; Franchini, G. *Science* **1989**, *244*, 694.
11. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. *Virology* **2005**, *339*, 213.
12. Wang, T.; Zhang, Z.; Wallace, O. B.; Deshpande, M.; Fang, H.; Yang, Z.; Zadjura, L. M.; Tweedie, D. L.; Huang, S.; Zhao, F.; Ranadive, S.; Robinson, B. S.; Gong, Y. F.; Ricarrdi, K.; Spicer, T. P.; Deminie, C.; Rose, R.; Wang, H. G.; Blair, W. S.; Shi, P. Y.; Lin, P. F.; Colonno, R. J.; Meanwell, N. A. *Journal of medicinal chemistry* **2003**, *46*, 4236.
13. Kwon, Y. D.; LaLonde, J. M.; Yang, Y.; Elban, M. A.; Sugawara, A.; Courter, J. R.; Jones, D. M.; Smith, A. B., 3rd; Debnath, A. K.; Kwong, P. D. *PloS one* **2014**, *9*, e85940.
14. Courter, J. R.; Madani, N.; Sodroski, J.; Schon, A.; Freire, E.; Kwong, P. D.; Hendrickson, W. A.; Chaiken, I. M.; Lalonde, J. M.; Smith, A. B., 3rd. *Accounts of chemical research* **2014**.
15. Kwon, Y. D.; Finzi, A.; Wu, X.; Dogo-Isonagie, C.; Lee, L. K.; Moore, L. R.; Schmidt, S. D.; Stuckey, J.; Yang, Y.; Zhou, T.; Zhu, J.; Vicic, D. A.; Debnath, A. K.; Shapiro, L.; Bewley, C. A.; Mascola, J. R.; Sodroski, J. G.; Kwong, P. D. *Proceedings of the National Academy of Sciences of the United States of America* **2012**, *109*, 5663.
16. Lin, P. F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y. F.; Wang, H. G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C. B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. *Proceedings of the National Academy of Sciences of the United States of America* **2003**, *100*, 11013.
17. Li, Z.; Zhou, N.; Sun, Y.; Ray, N.; Lataillade, M.; Hanna, G. J.; Krystal, M. *Antimicrobial agents and chemotherapy* **2013**.

18. Si, Z.; Madani, N.; Cox, J. M.; Chruma, J. J.; Klein, J. C.; Schon, A.; Phan, N.; Wang, L.; Biorn, A. C.; Cocklin, S.; Chaiken, I.; Freire, E.; Smith, A. B., 3rd; Sodroski, J. G. *Proc Natl Acad Sci U S A* **2004**, *101*, 5036.
19. Nowicka-Sans, B.; Gong, Y. F.; McAuliffe, B.; Dicker, I.; Ho, H. T.; Zhou, N.; Eggers, B.; Lin, P. F.; Ray, N.; Wind-Rotolo, M.; Zhu, L.; Majumdar, A.; Stock, D.; Lataillade, M.; Hanna, G. J.; Matiskella, J. D.; Ueda, Y.; Wang, T.; Kadow, J. F.; Meanwell, N. A.; Krystal, M. *Antimicrobial agents and chemotherapy* **2012**.
20. Charpentier, C.; Larrouy, L.; Visseaux, B.; Landman, R.; Levittas, M.; Storto, A.; Damond, F.; Yazdanpanah, Y.; Yeni, P.; Brun-Vezinet, F.; Descamps, D. *The Journal of antimicrobial chemotherapy* **2012**.
21. Singh, I. P.; Chauthe, S. K. *Expert opinion on therapeutic patents* **2011**, *21*, 399.
22. Yang, Z.; Zadjura, L. M.; Marino, A. M.; D'Arienzo, C. J.; Malinowski, J.; Gesenberg, C.; Lin, P. F.; Colonno, R. J.; Wang, T.; Kadow, J. F.; Meanwell, N. A.; Hansel, S. B. *Journal of pharmaceutical sciences* **2010**, *99*, 2135.
23. Cheeseright, T.; Mackey, M.; Rose, S.; Vinter, A. *Journal of chemical information and modeling* **2006**, *46*, 665.
24. Cheeseright, T.; Mackey Phd, M.; Rose Phd, S.; Vinter Phd, A. *Expert opinion on drug discovery* **2007**, *2*, 131.
25. Cheeseright, T. J.; Holm, M.; Lehmann, F.; Luik, S.; Gottert, M.; Melville, J. L.; Laufer, S. *Journal of medicinal chemistry* **2009**, *52*, 4200.
26. Cheeseright, T. J.; Mackey, M. D.; Melville, J. L.; Vinter, J. G. *Journal of chemical information and modeling* **2008**, *48*, 2108.
27. Cheeseright, T. J.; Mackey, M. D.; Scoffin, R. A. *Current computer-aided drug design* **2011**, *7*, 190.
28. Collins, J. C.; Armstrong, A.; Chapman, K. L.; Cordingley, H. C.; Jaxa-Chamiec, A. A.; Judd, K. E.; Mann, D. J.; Scott, K. A.; Tralau-Stewart, C. J.; Low, C. M. R. *Medchemcomm* **2013**, *4*, 1148.
29. Kirpotina, L. N.; Khlebnikov, A. I.; Schepetkin, I. A.; Ye, R. D.; Rabiet, M. J.; Jutila, M. A.; Quinn, M. T. *Molecular pharmacology* **2010**, *77*, 159.
30. Low, C. M.; Buck, I. M.; Cooke, T.; Cushnir, J. R.; Kalindjian, S. B.; Kotecha, A.; Pether, M. J.; Shankley, N. P.; Vinter, J. G.; Wright, L. *Journal of medicinal chemistry* **2005**, *48*, 6790.
31. Low, C. M.; Vinter, J. G. *Journal of medicinal chemistry* **2008**, *51*, 565.
32. Mackey, M. D.; Melville, J. L. *Journal of chemical information and modeling* **2009**, *49*, 1154.
33. Webster, S. P.; Binnie, M.; McConnell, K. M.; Sooy, K.; Ward, P.; Greaney, M. F.; Vinter, A.; Pallin, T. D.; Dyke, H. J.; Gill, M. I.; Warner, I.; Seckl, J. R.; Walker, B. R. *Bioorganic & medicinal chemistry letters* **2010**, *20*, 3265.
34. Biorn, A. C.; Cocklin, S.; Madani, N.; Si, Z.; Ivanovic, T.; Samanen, J.; Van Ryk, D. I.; Pantophlet, R.; Burton, D. R.; Freire, E.; Sodroski, J.; Chaiken, I. M. *Biochemistry* **2004**, *43*, 1928.
35. Mowbray, C. E.; Bell, A. S.; Clarke, N. P.; Collins, M.; Jones, R. M.; Lane, C. A.; Liu, W. L.; Newman, S. D.; Paradowski, M.; Schenck, E. J.; Selby, M. D.; Swain, N. A.; Williams, D. H. *Bioorganic & medicinal chemistry letters* **2011**, *21*, 6596.

36. Yang, Z.; Zadjura, L. M.; Marino, A. M.; D'Arienzo, C. J.; Malinowski, J.; Gesenberg, C.; Lin, P. F.; Colonno, R. J.; Wang, T.; Kadow, J. F.; Meanwell, N. A.; Hansel, S. B. *Journal of pharmaceutical sciences* **2010**, *99*, 2135.
37. Wang, T.; Yin, Z. W.; Zhang, Z. X.; Bender, J. A.; Yang, Z.; Johnson, G.; Yang, Z.; Zadjura, L. M.; D'Arieno, C. J.; Parker, D. D.; Gesenberg, C.; Yamanaka, G. A.; Gong, Y. F.; Ho, H. T.; Fang, H.; Zhou, N. N.; McAuliffe, B. V.; Eggers, B. J.; Fan, L.; Nowicka-Sans, B.; Dicker, I. B.; Gao, Q.; Colonno, R. J.; Lin, P. F.; Meanwell, N. A.; Kadow, J. F. *Journal of medicinal chemistry* **2009**, *52*, 7778.
38. Li, Z. F.; Zhou, N. N.; Sun, Y. N.; Ray, N.; Lataillade, M.; Hanna, G. J.; Krystal, M. *Antimicrobial agents and chemotherapy* **2013**, *57*, 4172.
39. Nowicka-Sans, B.; Gong, Y. F.; McAuliffe, B.; Dicker, I.; Ho, H. T.; Zhou, N. N.; Eggers, B.; Lin, P. F.; Ray, N.; Wind-Rotolo, M.; Zhu, L.; Majumdar, A.; Stock, D.; Lataillade, M.; Hanna, G. J.; Matiskella, J. D.; Ueda, Y.; Wang, T.; Kadow, J. F.; Meanwell, N. A.; Krystal, M. *Antimicrobial agents and chemotherapy* **2012**, *56*, 3498.
40. Segall, M.; Champness, E.; Obrezanova, O.; Leeding, C. *Chem Biodivers* **2009**, *6*, 2144.
41. Segall, M. D. *Current pharmaceutical design* **2012**, *18*, 1292.
42. Zentner, I.; Sierra, L. J.; Fraser, A. K.; Maciunas, L.; Mankowski, M. K.; Vinnik, A.; Fedichev, P.; Ptak, R. G.; Martin-Garcia, J.; Cocklin, S. *ChemMedChem* **2013**, *8*, 426.
43. Zentner, I.; Sierra, L. J.; Maciunas, L.; Vinnik, A.; Fedichev, P.; Mankowski, M. K.; Ptak, R. G.; Martin-Garcia, J.; Cocklin, S. *Bioorganic & medicinal chemistry letters* **2013**, *23*, 1132.
44. Kortagere, S.; Madani, N.; Mankowski, M. K.; Schon, A.; Zentner, I.; Swaminathan, G.; Princiotta, A.; Anthony, K.; Oza, A.; Sierra, L. J.; Passic, S. R.; Wang, X.; Jones, D. M.; Stavale, E.; Krebs, F. C.; Martin-Garcia, J.; Freire, E.; Ptak, R. G.; Sodroski, J.; Cocklin, S.; Smith, A. B., 3rd. *Journal of virology* **2012**, *86*, 8472.




Figure 1: Structures of entry inhibitors developed by Bristol-Myers Squibb and the New York Blood Bank. The chemical structures were drawn with ChemAxon software (Budapest, Hungary).




Figure 2: (a) Field-based template A containing a single conformation of compounds BMS-378806 (pink), BMS-488043 (lime green), and BMS-626529 (teal green) aligned based on their three-dimensional field point patterns. Negatively charged field points are shown in blue; positively charged field points are red; van der Waals/shape field points are displayed in yellow; centers of hydrophobicity are shown in orange. (b) Conformation 69 of BMS-626529 with its associated field points. This conformation was common to the top three templates identified and was used as the query structure for the Blaze (Cresset, Litlington, UK) field-based virtual screen





Figure 3: Steps involved in a Blaze (Cresset, Litlington, UK) field-based virtual screen experiment. (1) An active molecule is selected and converted to a relevant bioactive conformation. (2) Field points are added to this search ligand in the specified conformation to produce the Blaze pharmacophore seed. (3) The Blaze search query consists of the field point pattern of the pharmacophore seed, which is used to search the Blaze database by alignment of every structure based on field point patterns (of its up to 100 conformations). (4) Top scoring compounds are retrieved as three-dimensional alignments to the search query, along with their score (molecular similarity based on 50% shape, 50% fields).

(a)



(b)




Figure 4: (a) The individual models that comprise the oral non-CNS (central nervous system) drug profile and their respective importance to the profile. HIA = human intestinal absorption; hERG (human ether-à-go-go-related gene); IC_{50} = half-maximal inhibitory concentration; BBB = blood–brain barrier. (b) Plot showing the StarDrop (Optibrium, Ltd., Cambridge, UK)–derived logS versus the score from a multimetric oral non-CNS profile for the BMS and SC compounds.






Compound	IC ₅₀ YU-2 (μM)	IC ₅₀ AMLV (μM)
11 	13.1 ± 1.7	NA
12 	53.5 ± 3.0	NA
28 	33.7 ± 4.5	NA
32 	79.4 ± 11	NA
34 	153 ± 44	NA

Table 1: Structure and potency of compounds identified within this study with specific activity against HIV-1 YU-2. Chemical structures were drawn with ChemAxon software (Budapest, Hungary). NA = not active over concentration range tested.







Compound	JR-CSF	IC ₅₀ (μM)	
		HxBc2	AMLV
SC04			
	100 ± 30	ND	NA
SC07			
	0.98 ± 0.06	16.8 ± 6.2	NA
SC08			
	0.09 ± 0.01	0.19 ± 0.08	NA
SC11			
	0.0008 ± 0.0004	0.001 ± 0.0001	NA
SC26			
	0.002 ± 0.0001	0.0006 ± 0.00008	NA

Table 2: Structure and potency of second-generation compounds based on the dipyrrolidine core scaffold. Chemical structures were drawn with ChemAxon software (Budapest, Hungary). AMLV = amphotropic murine leukemia virus; NA = not active over concentration range tested; ND = not determined. Chemical structures were drawn with ChemAxon software (Budapest, Hungary).

Virus isolate	Subtype	IC ₅₀ (μM)	TC ₅₀ (μM)	Antiviral index (TC ₅₀ /IC ₅₀)
92UG037	A	25.2 ± 6.9	>100	> 3.97
91US004	B	0.195 ± 0.012		> 513
94US_33931N	B	0.0006 ± 0.0005		> 166,666
98US_MSC5016	C	3.9 ± 0.8		> 25.6
99UG_A07412M1	D	0.49 ± 0.06		> 204
HIV-2 CDC310319	NA	> 100		NA

Table 3: Therapeutic spectrum of SC26 against highly prevalent HIV-1 subtypes and HIV-2. IC₅₀ = half-maximal inhibitory concentration; NA = not applicable; TC₅₀ = half-maximal toxic concentration.



SC26

IC_{50} HxBc2 = 0.6 ± 0.08 nM